LIVZON PHARMAC. GRP H YC1 Financial Flexibility Index
LIVZON PHARMAC. GRP H YC1 financial flexibility index. LIVZON PHARMAC. GRP H YC1 (LP6) has a Financial Flexibility Index of 0.44x as of December 2025. Free cash flow of €3.72 Billion (operating CF €3.15 Billion minus capex €574.14 Million) represents 0% of total liabilities (€8.44 Billion). See LP6 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of LIVZON PHARMAC. GRP H YC1 (2021–2025)
Financial flexibility index of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. Historical Financial Flexibility Index trend for LIVZON PHARMAC. GRP H YC1 across 5 annual periods. Check LIVZON PHARMAC. GRP H YC1 earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
LIVZON PHARMAC. GRP H YC1 Financial Flexibility Index by Year (2021–2025)
LIVZON PHARMAC. GRP H YC1 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for LIVZON PHARMAC. GRP H YC1. For the full cash flow conversion analysis, see LP6 operating cash flow.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.44x | €3.72 Billion | €3.15 Billion | €8.44 Billion | ▲ +18.6% |
| 2024 | 0.37x | €3.55 Billion | €2.98 Billion | €9.55 Billion | ▼ -6.1% |
| 2023 | 0.40x | €4.07 Billion | €3.25 Billion | €10.28 Billion | ▲ +5.9% |
| 2022 | 0.37x | €3.71 Billion | €2.77 Billion | €9.93 Billion | ▼ -6.2% |
| 2021 | 0.40x | €3.21 Billion | €1.90 Billion | €8.06 Billion | — |